ImmunityBio (IBRX) has reached an important inflection point, with the first European patients receiving ANKTIVA plus BCG for BCG unresponsive non muscle invasive bladder cancer after conditional European Commission approval.
For investors tracking ImmunityBio, the latest treatment milestone in Europe lands after a choppy few weeks in the market, with the share price down 10.3% over the last day and 17.9% over the past month but still showing a 296.5% year to date share price return and a 276.1% total shareholder return over 12 months.
Scan beyond ImmunityBio and line up other oncology-focused plays with hand-picked 34 healthcare AI stocks that could benefit as immunotherapy and AI driven drug development continue to gain attention.
ImmunityBio now has an approved product and real-world use in Europe, yet the share price has swung sharply after a huge run this year. Does that recent volatility leave the stock overhyped or still reasonably priced?
Most Popular Narrative: 44% Undervalued
ImmunityBio’s most followed valuation storyline pegs fair value at $14.25 per share, compared with a last close of $8.01. This sets expectations high around what needs to go right from here.
The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.
The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.
See why 22 investors see ImmunityBio as 44% undervalued.
Result: Fair Value of $14.25 (UNDERVALUED)
Still, the ImmunityBio story can break if ANKTIVA remains the only meaningful revenue driver or if regulators and payers prove tougher than current analyst assumptions.
Find out about the key risks to this ImmunityBio narrative.
Next Steps
Sentiment around ImmunityBio is divided, which is often the time to move quickly, review the data independently, and consider both the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond ImmunityBio?
Do not stop with ImmunityBio. Use the Simply Wall Street Screener to widen your watchlist and pressure test your next moves before capital goes to work.
- Target resilient potential compounders by checking a 32 resilient stocks with low risk scores that filters for businesses with more defensive risk profiles.
- Hunt for quality at a sensible price by scanning a 42 high quality undervalued stocks that blends fundamentals with valuation checks.
- Spot lesser known opportunities early by running through a 21 high quality undiscovered gems that highlights under-followed companies with solid numbers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com